Taysha Gene Therapies Inc (TSHA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.34B
Last updated: Nov 17, 2026 at 11:06 AM ET
Taysha Gene Therapies Inc (TSHA) Earnings: Report Dates and Results
Taysha Gene Therapies (TSHA) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Taysha Gene Therapies reported EPS of -$0.10, above the -$0.14 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TSHA has an expected report date of Mar 17, 2027.
TSHA Earnings Call
The latest TSHA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 25 quarters below that had an estimate, TSHA beat 9, missed 13 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 936.36% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.10 | -$0.14 | -$0.14 - -$0.10 | +28.57% | Beat | N/A | 4 | 0 up, 3 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.13 | -$0.11 | -$0.12 - -$0.09 | -18.18% | Miss | N/A | 4 | 1 up, 0 down | Aug 11, 2026 | N/A |
| Mar 31, 2026 | -$0.11 | -$0.10 | -$0.12 - -$0.07 | -10.00% | Miss | N/A | 5 | 1 up, 0 down | May 6, 2026 | N/A |
| Dec 31, 2025 | -$0.07 | -$0.10 | -$0.12 - -$0.07 | +23.43% | Beat | N/A | 5 | 1 up, 0 down | Mar 19, 2026 | $5.49M |
| Sep 30, 2025 | -$0.09 | -$0.09 | -$0.12 - -$0.06 | 0.00% | In line | N/A | 5 | N/A | Nov 4, 2025 | N/A |
| Jun 30, 2025 | -$0.08 | -$0.07 | -$0.09 - -$0.05 | -14.29% | Miss | N/A | 4 | 1 up, 0 down | Aug 12, 2025 | $1.99M |
| Mar 31, 2025 | -$0.08 | -$0.08 | -$0.10 - -$0.08 | 0.00% | In line | N/A | 2 | 1 up, 0 down | May 15, 2025 | $2.30M |
| Dec 31, 2024 | -$0.07 | -$0.08 | N/A | +12.50% | Beat | -107.6% | N/A | 0 up, 0 down | Feb 26, 2025 | $2.02M |
| Sep 30, 2024 | -$0.07 | -$0.09 | -$0.11 - -$0.08 | +22.22% | Beat | N/A | 10 | 0 up, 0 down | Nov 13, 2024 | $1.79M |
| Jun 30, 2024 | -$0.09 | -$0.10 | -$0.80 - -$0.08 | +10.00% | Beat | N/A | 11 | 2 up, 0 down | Aug 12, 2024 | $1.11M |
| Mar 31, 2024 | -$0.10 | -$0.09 | -$0.19 - -$0.07 | -11.11% | Miss | N/A | 10 | 0 up, 0 down | May 14, 2024 | $3.41M |
| Dec 31, 2023 | $0.92 | -$0.11 | -$0.24 - -$0.07 | +936.36% | Beat | N/A | 10 | 0 up, 0 down | Mar 19, 2024 | $3.60M |
| Sep 30, 2023 | -$0.93 | -$0.17 | -$0.31 - -$0.09 | -447.06% | Miss | N/A | 10 | 0 up, 0 down | Nov 14, 2023 | $4.75M |
| Jun 30, 2023 | -$0.38 | -$0.31 | -$0.39 - -$0.20 | -22.58% | Miss | N/A | 9 | 0 up, 0 down | Aug 14, 2023 | $2.40M |
| Mar 31, 2023 | -$0.28 | -$0.38 | -$0.39 - -$0.25 | +26.32% | Beat | N/A | 10 | 0 up, 0 down | May 11, 2023 | $4.71M |
| Dec 31, 2022 | -$0.99 | -$0.33 | -$0.57 - $0.48 | -200.00% | Miss | N/A | 13 | 0 up, 0 down | Mar 28, 2023 | $2.50M |
| Sep 30, 2022 | -$0.64 | -$0.82 | -$0.99 - -$0.66 | +21.95% | Beat | N/A | 14 | 2 up, 0 down | Nov 8, 2022 | N/A |
| Jun 30, 2022 | -$0.84 | -$1.06 | N/A | +20.75% | Beat | N/A | N/A | 0 up, 0 down | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$1.31 | -$1.10 | -$1.43 - -$0.75 | -19.09% | Miss | N/A | 15 | 0 up, 0 down | May 16, 2022 | N/A |
| Dec 31, 2021 | -$1.32 | -$1.25 | -$1.62 - -$0.96 | -5.60% | Miss | N/A | 16 | N/A | Mar 31, 2022 | N/A |
| Sep 30, 2021 | -$1.35 | -$1.09 | -$1.28 - -$0.93 | -23.85% | Miss | N/A | 12 | 0 up, 1 down | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$1.09 | -$0.86 | -$0.95 - -$0.63 | -26.74% | Miss | N/A | 12 | N/A | Aug 16, 2021 | N/A |
| Mar 31, 2021 | -$0.87 | -$0.65 | -$0.74 - -$0.17 | -33.85% | Miss | N/A | 6 | N/A | May 11, 2021 | N/A |
| Dec 31, 2020 | -$1.04 | -$0.37 | -$0.58 - -$0.17 | -181.08% | Miss | N/A | 4 | N/A | Mar 3, 2021 | N/A |
| Sep 30, 2020 | -$1.28 | $0.07 | N/A | N/A | N/A | N/A | 2 | N/A | Nov 12, 2020 | N/A |
| Jun 30, 2020 | -$1.28 | -$1.28 | N/A | 0.00% | In line | N/A | N/A | N/A | Sep 25, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.32, after -$0.33 the year before. It was -$3.60 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.32 | N/A |
| Dec 31, 2024 | -$0.33 | N/A |
| Dec 31, 2023 | -$0.67 | N/A |
| Dec 31, 2022 | -$3.78 | N/A |
| Dec 31, 2021 | -$4.63 | N/A |
| Dec 31, 2020 | -$3.60 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,600 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,574 | 17 | |
| 2026Q2 | Jun 30, 2026 | 6,428 | 16 | |
| 2026Q1 | Mar 31, 2026 | 8,380 | 17 | |
| 2025Q4 | Dec 31, 2025 | 8,828 | 15 | |
| 2025Q3 | Sep 30, 2025 | 7,058 | 15 | |
| 2025Q2 | Jun 30, 2025 | 5,580 | 13 | |
| 2025Q1 | Mar 31, 2025 | 7,040 | 16 | |
| 2024Q4 | Dec 31, 2024 | 4,364 | 12 |
2026Q3 Earnings Call
Opening remarks
Stephanie Webster Conference Call Host Thank you. Good morning, and welcome to Taysha's Third Quarter 2026 Financial Results and Corporate Update Conference Call. Earlier today, Taysha issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the course of disease in the patients we seek to treat; our research, development, and regulatory plans for our product candidates, including the timing of initiating additional trials, reporting data from our clinical trials, and making regulatory submissions; the timing or outcomes of communications with the FDA on the regulatory pathway for TSHA-102; the potential for the product candidate to receive regulatory approval from the FDA or equivalent foreign regulatory agencies; our ability to realize the benefits of Breakthrough Therapy designation for TSHA-102; our ability to drive long-term value for stockholders; and the market opportunity for our program. This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway, and future operating results; discovery and development of product candidates, including our potential nomination of an additional gene therapy candidate in the first half of 2027; manufacturing and commercial readiness activities; strategic alliances; and intellectual property, as well as matters that are not historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements. For a list and description of the risks and uncertainties that we face, please see the reports we have filed with the SEC, including our annual report on Form 10-K for the full year ended December 31, 2025, which we filed on March 19, 2026. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 12, 2026. Taysha undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities laws. With that, I would now like to turn the call over to our CEO, Sean Nolan.
Sean Nolan CEO Thank you, Stephanie, and welcome, everyone, to our Third Quarter 2026 Financial Results and Corporate Update Conference Call.
Frequently Asked Questions About TSHA
When is Taysha Gene Therapies's next earnings date?
Taysha Gene Therapies's next earnings report is expected for Mar 17, 2027.
Did TSHA beat earnings estimates last quarter?
Yes. Taysha Gene Therapies reported EPS of -$0.10 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 28.57% surprise.
What EPS do analysts expect from TSHA next quarter?
The consensus EPS estimate for Taysha Gene Therapies for the quarter ending Dec 31, 2026 is -$0.13 from 14 analysts, with estimates from -$0.15 to -$0.12.
How often does TSHA beat earnings estimates?
Taysha Gene Therapies beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +2.75%.
TSHA pages: Overview, Earnings, Forecast, Financials, Competitors